Trial Profile
Phase I/II Study With Lapatinib Plus Trametinib in Patients With Metastatic KRAS Mutant Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Trametinib (Primary) ; Antineoplastics; Docetaxel
- Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms M14LTK
- 29 Oct 2020 Status changed from recruiting to completed.
- 08 Nov 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2018.
- 10 Nov 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.